Abstract | BACKGROUND: METHODS: Twenty-one patients with CRSwNP were included in the study, along with 15 control patients scheduled for dacryocystorhinostomy. A polypoid tissue biopsy was taken under local anesthesia, and 15 CRSwNP patients were scheduled for endoscopic sinus surgery after 3 weeks of oral methylprednisolone. Posttreatment biopsies were performed perioperatively. Pre- and posttreatment endoscopic polyp grades were determined, as were symptom scores regarding nasal obstruction, headache, and nasal discharge using a visual analog scale (VAS). SP-A and SP-D levels were measured using enzyme-linked immunosorbent assay and the results were compared. RESULTS: All patients reported relief from clinical symptoms through VAS after methylprednisolone treatment. The posttreatment polyp grade was reduced (p < 0.0001). SP-A and SP-D levels did not yield a significant difference between CRSwNP patients and controls (p = 0.25 and p = 0.13, respectively). Statistically significant up-regulation was detected in SP-A and SP-D levels after oral methylprednisolone (p = 0.0002 and p = 0.0004, respectively). CONCLUSION: In this study, significant up-regulation of SP-A and SP-D was revealed in patients with CRSwNP after systemic steroid treatment. The role of SP-A and SP-D up-regulation in CRSwNP pathogenesis and therapeutic outcomes of corticosteroids have potential importance for the introduction of new therapeutic modalities that are more effective and produce fewer adverse effects.
|
Authors | Serkan Salman, Meltem Esen Akpinar, Ozgur Yigit, Uzay Gormus |
Journal | American journal of rhinology & allergy
(Am J Rhinol Allergy)
2012 Mar-Apr
Vol. 26
Issue 2
Pg. e76-80
ISSN: 1945-8932 [Electronic] United States |
PMID | 22487281
(Publication Type: Journal Article)
|
Chemical References |
- Adrenal Cortex Hormones
- Pulmonary Surfactant-Associated Protein A
- Pulmonary Surfactant-Associated Protein D
- Methylprednisolone
|
Topics |
- Adrenal Cortex Hormones
(therapeutic use)
- Chronic Disease
- Disease Progression
- Humans
- Immunity, Innate
(drug effects)
- Methylprednisolone
(administration & dosage, adverse effects)
- Nasal Mucosa
(drug effects, metabolism)
- Nasal Polyps
(complications, drug therapy, immunology)
- Pulmonary Surfactant-Associated Protein A
(genetics, metabolism)
- Pulmonary Surfactant-Associated Protein D
(genetics, metabolism)
- Rhinitis
(complications, drug therapy, immunology)
- Sinusitis
(complications, drug therapy, immunology)
- Treatment Outcome
- Up-Regulation
|